PTO/SB/08A/B (09-06)
Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 7

Complete if Known	
Application Number	10/763,953-Conf. #5062
Filing Date	January 23, 2004
First Named Inventor	Xianqi KONG
Art Unit	1626
Examiner Name	J. M. Nolan
Attorney Docket Number	NBI-193

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (*if known*)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
/JN/	A1*	US-4,324,794	04/1982	Tidwell et al.	
	A2*	US-4,397,863	08/1983	Tidwell et al.	
	A3*	US-4,515,625	05/1985	Burow, Jr.	
	A4*	US-4,522,811	06-11-1985	Eppstein et al.	
	A5*	US-4,619,942	10/1986	Tidwell et al.	
	A6*	US-4,933,347	06/1990	Tidwell et al.	
	A7*	US-4,940,723	07/1990	Tidwell et al.	
	A8*	US-4,963,589	10/1990	Tidwell et al.	
	A9*	US-5,202,320	04/1993	Tidwell et al.	
	A10*	US-5,206,236	04/1993	Tidwell et al.	
	A11*	US-5,246,965	09/1993	Main	
	A12*	US-5,374,548	12-20-1994	Caras	
	A13*	US-5,387,742	02-07-1995	Cordell	
	A14*	US-5,399,311	03/1995	Kasai et al.	
	A15*	US-5,428,051	06/1995	Tidwell et al.	
	A16*	US-5,441,870	08-15-1995	Seubert et al.	
	A17*	US-5,451,700	09/1995	Morrissey et al.	
	A18*	US-5,521,189	05/1996	Boykin et al.	
	A19*	US-5,538,845	07/1996	Knops et al.	
	A20*	US-5,547,841	08/1996	Marotta et al.	
	A21*	US-5,552,426	09-03-1996	Lunn et al.	
	A22*	US-5,574,059	11/1996	Regunathan et al.	
	A23*	US-5,578,631	11/1996	Tidwell et al.	
	A24*	US-5,594,138	01/1997	Dykstra et al.	
	A25*	US-5,602,172	02/1997	Boykin et al.	
	A26*	US-5,605,811	02-25-1997	Seubert et al.	
	A27*	US-5,606,058	02/1997	Boykin et al.	
	A28*	US-5,612,363	03/1997	Mohan et al.	
	A29*	US-5,622,955	04/1997	Boykin et al.	
	A30*	US-5,627,184	05/1997	Boykin et al.	
	A31*	US-5,639,755	06/1997	Dykstra et al.	
	A32*	US-5,643,562	07-01-1997	Kisilevsky et al.	
	A33*	US-5,643,935	07/1997	Dykstra et al.	
	A34*	US-5,667,975	09/1997	Dykstra et al.	
	A35*	US-5,668,166	09/1997	Tidwell et al.	
	A36*	US-5,668,167	09/1997	Tidwell et al.	
	A37*	US-5,686,456	11/1997	Boykin et al.	
	A38*	US-5,686,477	11/1997	Jarry et al.	
	A39*	US-5,686,496	11/1997	Anderskewitz et al.	
	A40*	US-5,720,936	02/1998	Wadsworth et al.	
	A41*	US-5,721,106	02/1998	Maggio et al.	
	A42*	US-5,723,288	03/1998	Dykstra et al.	
	A43*	US-5,723,495	03/1998	Hall et al.	
	A44*	US-5,726,197	03/1998	Clark et al.	
	A45*	US-5,728,375	03-17-1998	Kisilevsky et al.	

Examiner Signature	/Jason Nolan/	Date Considered	04/06/2007

PTO/SB/08A/B (09-06)
Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 2 of 7

Complete if Known	
Application Number	10/763,953-Conf. #5062
Filing Date	January 23, 2004
First Named Inventor	Xianqi KONG
Art Unit	1626
Examiner Name	J. M. Nolan
Attorney Docket Number	NBI-193

/JN/	A46*	US-5,731,332	03/1998	Anderskewitz et al.		
	A47*	US-5,792,782	08/1998	Dykstra et al.		
	A48*	US-5,811,633	09/1998	Wadsworth et al.		
	A49*	US-5,817,686	10/1998	Dykstra et al.		
	A50*	US-5,817,687	10/1998	Dykstra et al.		
	A51*	US-5,840,294	11-24-1998	Kisilevsky et al.		
	A52*	US-5,843,980	12/1998	Hall et al.		
	A53*	US-5,871,924	02/1999	Yarus et al.		
	A54*	US-5,935,982	08/1999	Dykstra et al.		
	A55*	US-5,939,440	08/1999	Dykstra et al.		
	A56*	US-5,972,328	10-26-1999	Kisilevsky et al.		
	A57*	US-5,972,969	10/1999	Dykstra et al.		
	A58*	US-6,008,247	12/1999	Boykin et al.		
	A59*	US-6,017,941	01/2000	Dykstra et al.		
	A60*	US-6,025,398	02/2000	Hall et al.		
	A61*	US-6,037,377	03/2000	Anderskewitz et al.		
	A62*	US-6,046,226	04/2000	Dykstra et al.		
	A63*	US-6,127,423	10/2000	Anderskewitz et al.		
	A64*	US-6,127,554	10/2000	Boykin et al.		
	A65*	US-6,133,281	10/2000	Gonzalez-Cadavid et al.		
	A66*	US-6,156,779	12/2000	Dykstra et al.		
	A67*	US-20030130303	07/2003	Coe et al.		
	A68*	US-6,172,104	01/2003	Tidwell et al.		
	A69*	US-6,197,824	03/2003	Schromm et al.		
	A70*	US-6,214,883	04/2003	Hall et al.		
	A71*	US-6,294,565	09/2003	Dykstra et al.		
	A72*	US-6,319,944	11/2003	Claiborne et al.		
	A73*	US-6,326,395	12/2003	Tidwell et al.		
	A74*	US-6,489,365	12/2003	Anderskewitz et al.		
	A75*	US-6,625,612	09/2003	Tal et al.		
	A76*	US-6,627,647	09/2003	Betageri		
	A77*	US-6,635,668	10/2003	Tidwell et al.		
	A78*	US-20010044468	11/2003	Hall et al.		
	A79*	US-20030083362	03/2003	Boykin et al.		
	A80*	US-20030199521	10/2003	Dykstra et al.		

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document — Country Code[3]-Number[4]-Kind Code[5] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
	B1	JP-7-279092	10-24-1995	Seiko Kagaku Kogyo Co. Ltd.		
	B2	EP-0518818-A2	12-16-1992	Ciba-Geigy AG		
	B3	WO-93/16036-A1	08-19-1993	Boehringer Ingelheim International GmbH		
	B4	WO-94/11341-A1	05-26-1994	Ciba-Geigy AG		
	B5	EP-0601977-A1	06-15-1994	Ciba-Geigy AG		
	B6	EP-0941991-B1	09-15-1999	University of North Carolina at Chapel Hill		

Examiner Signature	/Jason Nolan/	Date Considered	04/06/2007

PTO/SB/08A/B (09-06)
Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 3 of 7

Complete if Known	
Application Number	10/763,953-Conf. #5062
Filing Date	January 23, 2004
First Named Inventor	Xianqi KONG
Art Unit	1626
Examiner Name	J. M. Nolan
Attorney Docket Number	NBI-193

/JN/	B7	WO-95/19772-A1	07-27-1995	The University of North Carolina at Chapel Hill		
	B8	WO-96/15126-A1	05-23-1996	Georgia State University Research Foundation, Inc. et al.		
	B9	WO-96/28187-A1	09-19-1996	Queen's University at Kingston		
	B10	WO-98/13037-A1	04-02-1998	The Regents of the University of California		
	B11	WO-98/40381-A1	09-17-1998	Vertex Pharmaceuticals Incorporated		
	B12	WO-98/55454-A2	12-10-1998	Takeda Chemical Industries, Ltd.		
	B13	WO-00/04893-A2	02-03-2000	University of North Carolina at Chapel Hill		
	B14	WO-01/03680	01-18-2001	Isis Innovation Ltd.		
	B15	WO-01/03685-A2	01-18-2001	The University of North Carolina at Chapel Hill		
	B16	WO-01/32159-A2	05-10-2001	The University of North Carolina at Chapel Hill et al.		
	B17	WO-01/46175-A1	06-28-2001	The University of North Carolina at Chapel Hill et al.		
	B18	WO-01/85093-A2	11-15-2001	Neurochem, Inc.		
	B19	WO-02/02516-A2	01-10-2002	Thomas Jefferson University		
	B20	WO-02/34715-A1	05-02-2002	Boehringer Ingelheim Pharma KG		
	B21	WO-02/36588-A2	05-10-2002	Army Medical Research and Material Command		
	B22	WO-02/055025-A2	07-18-2002	The University of North Carolina at Chapel Hill et al.		
	B23	WO-02/058684-A2	08-01-2002	Combinatorx Incorporated		
	B24	WO-02/058697-A1	08-01-2002	Combinatorx Incorporated		
	B25	WO-02/062785-A1	08-15-2002	Boehringer Ingelheim Pharma AG		
	B26	WO-03/017994-A1	03-06-2003	Neurochem Inc.		
	B27	WO-03/103598-A2	12-18-2003	The University of North Carolina at Chapel Hill et al.		
	B28	WO-05/033065-A1	04-14-2005	The University of North Carolina at Chapel Hill et al.		
	B29	WO-05/079780-A1	09-01-2005	Neurochem (International) Limited		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	/Jason Nolan/	Date Considered	04/06/2007

PTO/SB/08A/B (09-06)
Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 4 of 7

Complete if Known	
Application Number	10/763,953-Conf. #5062
Filing Date	January 23, 2004
First Named Inventor	Xianqi KONG
Art Unit	1626
Examiner Name	J. M. Nolan
Attorney Docket Number	NBI-193

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
/JN/	C1	Askanas V, *et al.*, "New advances in the understanding of sporadic inclusion-body myositis and hereditary inclusion-body myopathies." Curr. Opin. Rheumatol. 7(6), 486-96 (1995 Nov)	
	C2	Askanas V, *et al.*, "Transfer of beta-amyloid precursor protein gene using adenovirus vector causes mitochondrial abnormalities in cultured normal human muscle." Proc. Nat'l Acad. Sci. U.S.A. 93(3), 1314-19 (1996 Feb)	
	C3	Bailly, C, *et al.*, "Sequence-selective binding to DNA of bis(amidinophenoxy)alkanes related to propamidine and pentamidine," Biochem J. 1997 Apr 1;323 (Pt 1):23-31	
	C4	Baldwin, *et al.*, "Molecular Biology, Genetics and Protein Chemistry of Prion Diseases," Research Advances in Alzheimer's Disease and Related Disorders," John Wiley and Sons, New York, 757-773 (1995)	
	C5	Bayer, TA, *et al.*, "Key factors in Alzheimer's disease: ß amyloid precursor protein processing, metabolism and intraneuronal transport," Brain Pathology 11, 111 (2001)	
	C6	Beekes, M, *et al.*, "Western blot mapping of disease-specific amyloid in various animal species and humans with transmissible spongiform encephalopathies using a high-yield purification method." J. Gen. Virol. 76(Pt 10), 2567-76 (1995 Oct)	
	C7	Benson, DA, *et al.*, "GenBank," Nucl. Acids Res. 28(1):15-18 (2000)	
	C8	Berge, *et al.*, "Pharmaceutical salts." J. Pharm. Sci. 66(1), 1-19 (1977 Jan)	
	C9	Bilik P., *et al.*, "Novel dications with unfused aromatic systems: trithiophene and trifuran derivatives of furimidazoline," CHEMBIOCHEM 2(78), 559-69 (2001)	
	C10	Boado, R.J., *et al.*, "Drug delivery of antisense molecules to the brain for treatment of Alzheimer's disease and cerebral AIDS," J. Pharm. Sci. 87(11), 1308-15 (1998 Nov)	
	C11	Bohrmann, B., *et al.*, "Self-assembly of ß-amyloid 42 is retarded by small molecular ligands at the stage of structural intermediates," J. Struct. Biol. 130(2-3), 232-46 (2000 Jun)	
	C12	Boykin, D. W *et al.*, "Anti-Pneumocystis carinii pneumonia activity of dicationic diaryl methylpyrimidines" European Journal of Medicinal Chemistry (1997), 32(12), 965-972	
	C13	Cardin, A.D, *et al.*, "Molecular modeling of protein-glycosaminoglycan interactions," Arteriosclerosis. 9(1), 21-32 (1989 Jan-Feb)	
	C14	Caughey, GH, *et al.*, "Bis(5-amidino-2-benzimidazolyl)methane and related amidines are potent, reversible inhibitors of mast cell tryptases," J Pharmacol Exp Ther. 1993 Feb;264(2):676-82	
	C15	Chauhan, P.M.S. et al., "Antiparasitic Agents: Part VI - Synthesis of 1,2-,1-3- & 1,4-Bis(4-substituted aryloxy)benzenes & Their Biological Activities," *Indian Journal of Chemistry*, Vol. 27B:38-42 (1988)	
	C16	Chauhan, PM, *et al.*, "Effect of new diamidines against Leishmania donovani infection," Indian J Exp Biol. 1993 Feb;31(2):196-8	
	C17	Chongprasert, S., *et al.*, "Effects of freeze-dry processing conditions on the crystallization of pentamidine isethionate," J. Pharm. Sci. 87(9), 1155-60 (1998 Sep)	
	C18	Contreras, J.M., *et al.*, "Aminopyridazines as acetylcholinesterase inhibitors." J. Med. Chem. 42(4), 730-41 (1999 Feb)	
	C19	Czarny A, *et al.*, "Analysis of van der Waals and Electrostatic Contributions in the Interactions of Minor Groove Binding Benzimidazoles with DNA," J. Am. Chem. Soc.; 1995; 117(16); 4716-4717	
	C20	De Clercq, E., "Diaryl Amidine Derivatives as Oncornaviral DNA Polymerase Inhibitors," *J. Med. Chem.*, Vol. 23:787-795 (1980)	

Examiner Signature	/Jason Nolan/	Date Considered	04/06/2007

PTO/SB/08A/B (09-06)
Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 5 of 7

Complete if Known	
Application Number	10/763,953-Conf. #5062
Filing Date	January 23, 2004
First Named Inventor	Xianqi KONG
Art Unit	1626
Examiner Name	J. M. Nolan
Attorney Docket Number	NBI-193

/JN/	C21	de Koning, EJ, *et al.*, "Diabetes mellitus in Macaca mulatta monkeys is characterised by islet amyloidosis and reduction in beta-cell population." Diabetologia 36(5), 378-84 (1993 May).	
	C22	Donkor, IO, *et al.*, "Pentamidine congeners: 2,2-butenebridged aromatic diamidines and diimidazolines as potential anti-Pneumocystis carinii pneumonia agents," J. Med. Chem. 37(26), 4554-57 (1994)	
	C23	Dubovi, EJ, *et al.*, "Inhibition of respiratory syncytial virus-host cell interactions by mono- and diamidines. Antimicrob Agents Chemother," 1981 Apr;19(4):649-56	
	C24	Dunbar PG, *et al.*, "Design, synthesis, and neurochemical evaluation of 2-amino-5-(alkoxycarbonyl)-3,4,5,6-tetrahydropyridines and 2-amino-5-(alkoxycarbonyl)-1,4,5,6-tetrahydropyrimidines as M1 muscarinic receptor agonists," J Med Chem. 1994 Aug 19;37(17):2774-82	
	C25	Fairley, TA, *et al.*, "Structure, DNA minor groove binding, and base pair specificity of alkyl- and aryl-linked bis(amidinobenzimidazoles) and bis(amidinoindoles)," J Med Chem. 1993 Jun 11;36(12):1746-53	
	C26	Frangione, B, *et al.*, "Familial cerebral amyloid angiopathy related to stroke and dementia." Amyloid. 8(Suppl 1), 36-42, Review (2001 Jul)	
	C27	Garcia-Sevilla J, *et al.*, "I2-imidazoline receptors in the healthy and pathologic human brain," Ann N Y Acad Sci. 1995 Jul 12;763:178-93	
	C28	Garcia-Sevilla JA, "Imidazoline receptor proteins in brains of patients with Alzheimer's disease." Neurosci. Lett. 247(2-3), 95-98 (1998 May)	
	C29	Geratz, JD, *et al.*, "Amidino-substituted aromatic heterocycles as probes of the specificity pocket of trypsin-like proteases," Arch Biochem Biophys. 1979 Oct 15;197(2):551-9	
	C30	Geratz, JD, *et al.*, "Inhibitory effect of amidino-substituted heterocyclic compounds on the amidase activity of plasmin and of high and low molecular weight urokinase and on urokinase-induced plasminogen activation," Thromb Res. 1981 Oct 1-15;24(1-2):73-83	
	C31	Geratz, JD, *et al.*, "Novel bis(benzamidino) compounds with an aromatic central link. Inhibitors of thrombin, pancreatic kallikrein, trypsin, and complement," J Med Chem. 1976 May;19(5):634-9	
	C32	Gervais, F, "Amyloid - Those Deadly Fibrils." Eur. Biopham. Review, 40-42 (Autumn 2001)	
	C33	Giamarellou, H, *et al.*, 'Methicillin resistant' Staphylococcus aureus infections during 1978-79: clinical and bacteriologic observations," J. Antimicrob. Chemother. 1981 7: 649-655	
	C34	Glenner, GG, *et al.*, "Alzheimer's disease and Down's syndrome: sharing of a unique cerebrovascular amyloid fibril protein." Biochem. Biophys. Res. Commun. 122(3), 1131-35 (1984 Aug)	
	C35	Glenner, GG, *et al.*, "Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein." Biochem. Biophys. Res. Commun. 120(3), 885-90 (1984 May)	
	C36	Golde, TE, "Alzheimer disease therapy: Can the amyloid cascade be halted?" J. Clin. Invest. 111, 11-18 (2003)	
	C37	Gouras, GK, "Current theories for the molecular and cellular pathogenesis of Alzheimer's disease," Exp. Rev. Mol. Med. (31 May 2001), http://www-ermm.cbcu.cam.ac.uk/01003167h.htm	
	C38	Hall, JE, *et al.*, "Anti-Pneumocystis activities of aromatic diamidoxime prodrugs," Antimicrob Agents Chemother. 1998 Mar;42(3):666-74	
	C39	Hardy J, Selkoe DJ., "The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics." Science 297(5580), 353-56 (2002 Jul)	
	C40	Huang, T.L. , *et al.*, "Synthesis and anti-Pneumocystis carinii activity of piperidine-linked aromatic diimidazolines," Bioorg. Med. Chem. Lett. 6(17), 2087-90 (1996)	

Examiner Signature	/Jason Nolan/	Date Considered	04/06/2007

PTO/SB/08A/B (09-06)
Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 6 of 7

Complete if Known	
Application Number	10/763,953-Conf. #5062
Filing Date	January 23, 2004
First Named Inventor	Xianqi KONG
Art Unit	1626
Examiner Name	J. M. Nolan
Attorney Docket Number	NBI-193

/JN/	C41	Jones SK, *et al.*, "Novel pentamidine analogs in the treatment of experimental Pneumocystis carinii pneumonia." Antimicrob. Agents Chemother. 34(6), 1026-30 (1990 Jun)	
	C42	Lambert MP, *et al.*, "Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins." Proc. Nat'l Acad. Sci. U.S.A. 95(11), 6448-53 (1998 May)	
	C43	Lansiaux, A *et al.*, "Distribution of furamidine analogues in tumor cells: influence of the number of positive charges," J Med Chem. 2002 May 9;45(10):1994-2002	
	C44	Lorenzo A, *et al.*, "Pancreatic islet cell toxicity of amylin associated with type-2 diabetes mellitus," Nature 368(6473), 756-60 (1994 Apr)	
	C45	Mayeux, R, *et al.*, "Drug Therapy. Treatment of Alzheimer's Disease," New Engl. J. Med. 341(22), 1670-79 (1999)	
	C46	Messer WS Jr, *et al.*, "Synthesis and biological characterization of 1,4,5,6-tetrahydropyrimidine and 2-amino-3,4,5,6-tetrahydropyridine derivatives as selective m1 agonists," J Med Chem. 1997 Apr 11;40(8):1230-46	
	C47	Nandi G., *et al.*, "Synthesis, spectroscopic properties and antileishmanial screening of some pentamidine analogs," J. Indian Chem. Soc. 70(6), 527-31 (1993)	
	C48	Opie EL, "On the relation of chronic interstitial pancreatitis to the islands of Langerhans and to diabetes mellitus." J. Exp. Med. 5, 397-428 (1900-01)	
	C49	Parrish RF,*et al.*, "Structure-activity relationships for the inhibition of acrosin by benzamidine derivatives," J Med Chem. 1978 Nov;21(11):1132-6	
	C50	Ren, J, *et al.*, "Molecular recognition of a RNA:DNA hybrid structure," J Am Chem Soc. 2001 Jul 11;123(27):6742-3	
	C51	Reynolds IJ, *et al.*, "Pentamidine is an N-methyl-D-aspartate receptor antagonist and is neuroprotective in vitro," J Neurosci. 1992 Mar;12(3):970-5	
	C52	Reynolds IJ, *et al.*, "Studies on the effects of several pentamidine analogues on the NMDA receptor," Eur J Pharmacol. 1993 Jan 15;244(2):175-9	
	C53	Rupniak, N.M., *et al.*, "Reversal of cognitive impairment by heptyl physostigmine, a long-lasting cholinesterase inhibitor, in primates." J. Neurol. Sci. 107(2), 246-49 (1992 Feb)	
	C54	Selkoe, DJ, "Alzheimer's Disease: Genes, Proteins, and Therapy," Physiol. Rev. 81(2), 741-66 (April 2001)	
	C55	Silverman, RB, " The Organic Chemistry of Drug Design and Drug Action," Academic Press, Chapter 8 (1992)	
	C56	Soto J, *et al.*, "Dissociation between I2-imidazoline receptors and MAO-B activity in platelets of patients with Alzheimer's type dementia." J. Psychiatr. Res. 33(3), 251-27 (1999 May-Jun)	
	C57	Steck, EA, *et al.*, "Leishmania donovani, Plasmodium berghei, Trypanosoma rhodesiense: antiprotozoal effects of some amidine types," Exp Parasitol. 1981 Dec;52(3):404-13	
	C58	Tao Bin, *et al.*, "Novel bisbenzamidines and bisbenzimidazolines as noncompetitive NMDA receptor antagonists," Bioorg. Med. Chem. Lett. 9(9), 1299-1304 (1999)	
	C59	Tidwell, RR, et al "Strategies for anticoagulation with synthetic protease inhibitors. Xa inhibitors versus thrombin inhibitors," Thromb Res. 1980 Aug 1;19(3):339-49	
	C60	Tidwell, RR, et al "Analogues of 1,5-bis(4-amidinophenoxy)pentane (pentamidine) in the treatment of experimental Pneumocystis carinii pneumonia," J Med Chem. 1990 Apr;33(4):1252-7	
	C61	Tidwell, RR, *et al.* "Aromatic amidines: comparison of their ability to block respiratory syncytial virus induced cell fusion and to inhibit plasmin, urokinase, thrombin, and trypsin," J Med Chem. 1983 Feb;26(2):294-8	
↓	C62	Tidwell, RR, *et al.* "Diarylamidine derivatives with one or both of the aryl moieties consisting of an indole or indole-like ring. Inhibitors of arginine-specific esteroproteases," J Med Chem. 1978 Jul;21(7):613-23	

Examiner Signature	/Jason Nolan/	Date Considered	04/06/2007

PTO/SB/08A/B (09-06)
Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 7 of 7

Complete if Known	
Application Number	10/763,953-Conf. #5062
Filing Date	January 23, 2004
First Named Inventor	Xianqi KONG
Art Unit	1626
Examiner Name	J. M. Nolan
Attorney Docket Number	NBI-193

	/JN/	C63	Verner, E, *et al.*, "Development of serine protease inhibitors displaying a multicentered short (<2.3 .ANG.) hydrogen bond binding mode: Inhibitors of urokinase-type plasminogen activator and factor Xa," Journal of Medicinal Chemistry (2001), 44(17), 2753-2771	
		C64	Wang, L *et al.*, "Evaluation of the influence of compound structure on stacked-dimer formation in the DNA minor groove," Biochemistry. 2001 Feb 27;40(8):2511-21	
		C65	Weidner-Wells, M. A., *et al.* "Amidino benzimidazole inhibitors of bacterial two-component systems," Bioorganic & Medicinal Chemistry Letters (2001), 11(12), 1545-1548	
		C66	Westermark, P., *et al.*, "The pancreatic islet cells in insular amyloidosis in human diabetic and non-diabetic adults." Acta Pathol. Microbiol. Scand. [A] 81(3), 291-300 (1973 May)	
		C67	Wilson, WD, *et al.*, "The search for structure-specific nucleic acid-interactive drugs: effects of compound structure on RNA versus DNA interaction strength," Biochemistry. 1993 Apr 20;32(15):4098-104	
		C68	Wood, DH, *et al.*, "1,5-Bis(4-amidinophenoxy)pentane (pentamidine) is a potent inhibitor of [3H]idazoxan binding to imidazoline I2 binding sites." Eur. J. Pharmacol. 353(1), 97-103 (1998 Jul)	
		C69	Wood, DH, *et al.*, "Pentamidine is a potent inhibitor of [3H]idazoxan binding to imidazoline I2 receptors." Ann. N.Y. Acad. Sci. 881, 110-13 (1999 Jun)	
		C70	Zhang, *et al.*, "Biochemical characterization of the gamma-secretase activity that produces beta-amyloid peptides." Biochemistry 40(16), 5049-55 (2001 Apr)	
		C71	Zhang, *et al.*, "Enantioselective synthesis of oxiranes by the reactions of dimethylsulfonium methylide and aromatic aldehydes and ketones in the presence of chiral micelles." Tetrahedron: Asymmetry 8(16), 2723-25 (1997)	
↓		C72	Zhang, *et al.*, "Calpain inhibitor I increases beta-amyloid peptide production by inhibiting the degradation of the substrate of gamma-secretase. Evidence that substrate availability limits beta-amyloid peptide production." J Biol Chem. 274(13):8966-72 1999 Mar	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1]Applicant's unique citation designation number (optional). [2]Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	/Jason Nolan/	Date Considered	04/06/2007